Replies to post #291619 on NorthWest Biotherapeutics Inc (NWBO)

[iwasadiver]

I don’t feel it’s going to be a buyout for a while. Maybe a partnership on some development. But I think BMY sees beyond PD-1 and may be willing to partner to get to the next bigger thing that NWBO has the recipe for. Either way I see, in the end, something beyond $50-75/share. I know that people are rolling their eyes at this but I’m looking 2-4 years from now. I think we’ll settle in the $20-30/share range in the next year, after initial approvals in the UK and then the US. The generation of revenue this quarter is only the beginning of what’s going to occur from here on and as Sawston expands as we wait for approvals. That number is going to increase significantly which keeps adding to the legitimacy of NWBO as we cross $3-8/share by fall/winter (I think a spike after TLD will get over bought and settle back) after 2 more quarters of earnings and TLD, new announcements before/during November, etc. This will pick up institutional investment which has been on the sidelines and we’ll start rolling as a real company that then will have regular PR firms, and the ability to hire proper numbers of people to do all the various work 3 people are now doing. The slow roll has begun in my opinion and has been shown by the steady share price rise once the initial reaction occurred. It’s just my thoughts, but why I’m still buying.